Abstract 516P
Background
Patients (pts) with primary CNS tumors are often excluded from early phase clinical trials because of doubts regarding the blood brain penetration, adherence to study treatment and use of corticosteroids in immunotherapy clinical trials. Scores built to help selectection of pts that would be good candidates for early phase clinical trials such as the Royal Marsden Score (RMH) or the Gustave Roussy Immune Score (GRIm) are not relevant to pts with primary CNS. We aimed to determine factors associated with prognosis to help physicians referring pts.
Methods
We conducted a retrospective analysis of all pts treated for a CNS tumor and enrolled in an early phase clinical trials at the Drug Development Department at Gustave Roussy between January 2013 and December 2022. Descriptive statistics were used to present the population and a multivariate Cox regression was used to determine prognostic factors in uni and multivariate analysis on overall survival (OS).
Results
A total of 108 pts were included in the study. Median age was 47 (18-82), most males (F/M=35/73), 44% were symptomatic in the three months before study entry, 46% had a multifocal disease at C1D1. The ratio between low grade glioma (LGG) and high grade glioma (HGG) according to the new molecular classification of 2021 were 24/84. Molecular alterations were: IDH mutation (59%), MGMT methylation (14.2%, 94 unknown), 1p19q codeletion (19.7%, 53 unkown). Targeted therapies were the most common drug used (44%), followed by immunotherapy (33.%) and epigenetic drugs (8.4%). Pts harbouring a BRAF mutation treated with a specific target therapy were 12; pts with an FGFR mutation or fusion treated in the same setting were 18. Median progression free survival (PFS) was 9.7 months, 40% of pts were progressing at 3 months. Altogether, 34% of pts were alive at 6 months. In multivariate analysis, lymphocyte counts ≥900/mm3 (HR=0.7 95% CI 0.46 - 1.07), absence of steroids at baseline (HR=2.3 95% CI 1.5 - 3.5), absence of antiepileptic drugs at baseline (HR=2.06 95%CI 1.2 - 3.7) were associated with a better overall survival.
Conclusions
Corticosteroid use, lymphocyte count and use of antiepileptics will be used to build a new score that will be presented at the conference.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09